Worldwide Granulomatosis with Polyangiitis Industry to 2030 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Granulomatosis with Polyangiitis – Epidemiology Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the historical and forecasted epidemiology of GPA in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Key Findings
The disease epidemiology covered in the report provides historical and forecasted GPA epidemiology segmented as the Incident cases of granulomatosis with polyangiitis, Gender-specific cases of granulomatosis with polyangiitis and Age-specific cases of granulomatosis with polyangiitis. The report includes the incident scenario of GPA in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
Country-wise GPA Epidemiology
The epidemiology segment also provides the GPA epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total incident population of GPA in the 7MM countries was estimated to be 7,618 cases in 2020.
As per the estimates, the United States had the largest incidence of granulomatosis with polyangiitis in 2020. Among the EU5 countries, Germany had the largest incident population of GPA with 2,722 cases, followed by the UK in 2020. On the other hand, Italy had the lowest incident population of 150 cases in 2020.
Scope of the Report
- GPA report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
- GPA Epidemiology Report and Model provide an overview of the risk factors and global GPA trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report provides insight into the historical and forecasted patient pool of GPA in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
- The report helps recognize the growth opportunities in the 7MM concerning the patient population.
- The report assesses the disease risk and burden and highlights the unmet needs of granulomatosis with polyangiitis.
- The report provides the segmentation of the GPA epidemiology by incident cases of GPA in the 7MM
- The report provides the segmentation of the GPA epidemiology by gender-specific cases of GPA in the 7MM.
- The report provides the segmentation of the GPA epidemiology by age-specific cases of GPA in the 7MM.
Report Highlights
- 10-year Forecast of GPA epidemiology
- 7MM Coverage
- Incident Cases of Granulomatosis with polyangiitis
- Gender-specific Cases of Granulomatosis with polyangiitis
- Age-specific Cases of Granulomatosis with polyangiitis
KOL Views
The publisher interviews KOLs and obtain SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
- What will be the growth opportunities in the 7MM for the patient population pertaining to GPA?
- What are the key findings pertaining to the granulomatosis with polyangiitis epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2018-2030)?
- What would be the total number of patients with granulomatosis with polyangiitis across the 7MM during the forecast period (2018-2030)?
- Among the EU5 countries, which country will have the highest number of patients during the forecast period (2018-2030)?
- At what CAGR the patient population is expected to grow by in the 7MM during the forecast period (2018-2030)?
- What are the disease risk, burdens, and unmet needs of granulomatosis with polyangiitis?
- What are the currently available treatments for granulomatosis with polyangiitis?
Reasons to Buy
GPA Epidemiology report will allow the user to:
- Develop business strategies by understanding the trends shaping and driving the global GPA market
- Quantify patient populations in the global granulomatosis with polyangiitis market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for granulomatosis with polyangiitis therapeutics in each of the markets covered
- Understand the magnitude of the granulomatosis with polyangiitis population by its incident cases.
- Understand the magnitude of the granulomatosis with polyangiitis population by its gender-specific cases.
- Understand the magnitude of the granulomatosis with polyangiitis population by its age-specific cases.
- The GPA epidemiology report and model were written and developed by Masters and PhD level epidemiologists
- The GPA Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources
Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Executive Summary of Granulomatosis with Polyangiitis
4. Disease Background and Overview
4.1. Introduction
4.2. Clinical Manifestation
4.3. Different Phenotypes of GPA
4.4. Etiology
4.5. Pathophysiology
4.6. Diagnosis
4.6.1. Differential Diagnosis
4.7. Treatment
4.8. Treatment Guidelines
5. Epidemiology and Population Patient
5.1. Key Findings
5.2. 7MM Total Incident cases of GPA
5.3. Epidemiology of Granulomatosis with Polyangiitis
5.4. The United States
5.5. EU5
6. Organizations contributing toward the fight against GPA
7. Patient Journey
8. Case Report
9. Appendix
9.1.Bibliography
9.2.Report Methodology
10. Publisher Capabilities
12. Disclaimer
13. About the Publisher
For more information about this report visit https://www.researchandmarkets.com/r/g3fygl
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
